ActivX Biosciences Inc., of La Jolla, Calif., added Nancy Dahl as vice president and general counsel.
Amgen Inc., of Thousand Oaks, Calif., elected Frank Biondi and Patricia Sueltz to its board.
Antisoma plc, of London, appointed Lloyd Kelland head of laboratory.
Applied Molecular Evolution Inc., of San Diego, promoted Jeffry Watkins to chief scientific officer and Keith Manchester to vice president of business development.
Aptus Genomics Inc., of Gaithersburg, Md., appointed Michael Brownstein, Neal Copeland and Nancy Jenkins to its scientific advisory board.
Atlas Venture, of Boston, added Peter Barrett to lead its investments in U.S. life sciences companies.
Biolex Inc., of Pittsboro, N.C., appointed John Irick senior vice president, corporate and business development.
Caprion Pharmaceuticals Inc., of Montreal, added Henry Nowak as chief financial officer and executive vice president, legal affairs.
Cardiome Pharma Corp., of Vancouver, British Columbia, appointed Richard Schwarz executive director, congestive heart failure.
Celera Genomics Group, of Rockville, Md., appointed David Block executive vice president of Celera and chief operating officer of Celera’s therapeutic business.
Cell Genesys Inc., of Foster City, Calif., added Michael Ramsay as vice president, manufacturing operations.
Cubist Pharmaceuticals Inc., of Lexington, Mass., added Michael Bonney as president and chief operating officer and Christopher Guiffre as vice president, general counsel and secretary.
GeneFormatics Inc., of San Diego, added Vincent Gotz as chief business officer.